此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

A Phase II Study Investigating Upfront Pazopanib In Metastatic Renal Cancer Renal Cancer (Panther) (Panther)

2014年6月11日 更新者:Centre of Experimental Medicine、Queen Mary University of London

A Phase II Study Investigating Upfront Pazopanib In Metastatic Clear Cell Renal Cancer (Panther)

The purpose of this study is to investigate if 14 weeks of pazopanib therapy prior to surgery (nephrectomy) is of benefit to patients with metastatic renal cancer. Ninety-five patients will be recruited into his study.

研究概览

地位

未知

详细说明

This is a Phase II, open label study evaluating pre-operative pazopanib treatment in previously untreated patients with metastatic clear cell renal cancer. This study follows a Simon 2 stage design

Patients will take pazopanib for 14 weeks followed by a nephrectomy. The drug will continue after nephrectomy until disease progression is documented. Patients will come off study once disease progression occurs, where they will then be followed for survival. Subsequent treatment at the discretion of the treating physician will be documented.

After surgery, all patients will be radiologically evaluated 8 weekly until progression. Standard radical nephrectomy with lymph node dissection will be performed on those patients who are deemed operable. The surgery can be laparoscopic or open. Those not deemed suitable for nephrectomy after 14 weeks of treatment will be offered a repeat biopsy.

研究类型

观察性的

注册 (预期的)

95

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

      • Basildon、英国
        • Basildon and Thurrock University Hospitals NHS Foundation Trust
      • Coventry、英国
        • University Hospitals Coventry & Warwickshire NHS Trust
      • Glasgow、英国
        • The Beatson West of Scotland Cancer Centre
      • London、英国
        • Barts and London Hospital NHS Trust
      • London、英国
        • Oncology & Clinical Haematology Trials Unit, Royal Free Hospital
      • London、英国
        • Oncology & Haematology Clinical Trials Unit, Guy's Hospital
      • Oxford、英国
        • Department of Oncology Oxford Cancer Centre
      • Southampton、英国
        • Southampton General Hospital
      • Southend、英国
        • Southend University Hospital Trust

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

取样方法

概率样本

研究人群

The study population for this trial are patients with confirmed clear cell carcinoma with measurable metastases on CT/MRI imaging (by RECIST). Only a component of clear cell is required.

描述

Inclusion Criteria:

  • Histopathologically confirmed clear cell carcinoma with measurable metastases on CT/MRI imaging (by RECIST v1.1). Only a component of clear cell is required.

    • No prior systemic treatment or nephrectomy for RCC. Palliative radiotherapy is acceptable to non target lesions.
    • Adequate organ function as defined by the following criteria:

      i. Total serum bilirubin ≤1.5 x uln (patients with gilbert's disease exempt) ii. Serum transaminases (ALT) <3 x uln iii. Calculated creatinine clearance >30ml/min iv. Absolute neutrophil count (ANC) ≥1000/mm3 without growth factor support v. Platelets ≥ 75,000/mm3

    • Signed and dated informed consent document indicating that the patient (or legally acceptable representative) has been informed of all the pertinent aspects of the trial prior to enrolment.
    • Willingness and ability to comply with scheduled visits, treatment plans and laboratory tests and other study procedures
    • ECOG performance status of 0, 1 or 2.
    • 18 years or above (no upper age limit) Male or female

Exclusion Criteria:

  • Congestive heart failure (class III or IV NYHA), myocardial infarction or coronary artery bypass graft/ stenting or stroke in the previous six months, ongoing severe or unstable arrhythmia requiring medication.

    • Previous treatment for renal cancer
    • Pregnancy or breastfeeding. Female patients must be surgically sterile, be postmenopausal, or must agree to use adequate contraception during the period of therapy.
    • Male patients must be surgically sterile or agree to use adequate contraception during the period of therapy.
    • Other severe acute or chronic medical or psychiatric condition, or laboratory abnormality that would in the judgement of the investigator, impart excess risk associated with study participation or study drug administration, or which, in the judgement of the investigator, would make the patient inappropriate for entry into this study
    • Prolonged QT interval >480msecs or a history of prolonged QT interval >480msecs
    • Ongoing major gastrointestinal disease including ulcerative colitis, bleeding peptic ulcer disease or inflammatory bowel disease.
    • Bleeding diathesis
    • Current uncontrolled hypertension
    • Another malignancy requiring treatment within the last 5 years. Local prostate cancer not requiring hormone therapy or an asymptomatic raised PSA is acceptable.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Clinical benefit of 14 weeks of pre-operative pazopanib therapy, prior to nephrectomy using RECIST 1.1 criteria
大体时间:Interim analysis after 34 patients have 12 weeks of treatment
12 week CT scan will be compared to the baseline CT scan using RESIST criteria 1.1 to assess whether the patients have benefited from the upfront pazopanib treatment.
Interim analysis after 34 patients have 12 weeks of treatment

次要结果测量

结果测量
措施说明
大体时间
Surgical complications (blood loss, post operative complications, hospital stay)
大体时间:After the first 20 patients have had a nephrectomy
Following surgery information regarding the quantity of blood loss, time the surgery took, length of hospital stay and whether there were any surgical complications will be recorded.
After the first 20 patients have had a nephrectomy
Overall Survival
大体时间:After three years of study
Overall survival will be measured from start of treatment to time of death.
After three years of study
Progression free survival
大体时间:After all patients have progresssed
Progression free survival will be measured from start of study treatment to time of disease progression.
After all patients have progresssed
Local response of primary tumour to pazopanib
大体时间:After 12 weeks of study drug
After 12 weeks of study drug

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始

2010年7月1日

初级完成 (实际的)

2014年2月1日

研究完成 (预期的)

2014年12月1日

研究注册日期

首次提交

2011年10月4日

首先提交符合 QC 标准的

2012年1月13日

首次发布 (估计)

2012年1月19日

研究记录更新

最后更新发布 (估计)

2014年6月12日

上次提交的符合 QC 标准的更新

2014年6月11日

最后验证

2014年6月1日

更多信息

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅